Recent advances in clinical development of leukotriene B4 pathway drugs.

[1]  D. Bilton,et al.  Phase I Studies of Acebilustat: Biomarker Response and Safety in Patients with Cystic Fibrosis , 2016, Clinical and translational science.

[2]  P. Doevendans,et al.  BLT1 antagonist LSN2792613 reduces infarct size in a mouse model of myocardial ischaemia-reperfusion injury. , 2015, Cardiovascular research.

[3]  T. Dainichi,et al.  Resolvin E1 inhibits dendritic cell migration in the skin and attenuates contact hypersensitivity responses , 2015, The Journal of experimental medicine.

[4]  J. Olefsky,et al.  LTB4 causes macrophage–mediated inflammation and directly induces insulin resistance in obesity , 2015, Nature Medicine.

[5]  R. Thurmond,et al.  Effects of JNJ-40929837, a leukotriene A4 hydrolase inhibitor, in a bronchial allergen challenge model of asthma. , 2014, Pulmonary pharmacology & therapeutics.

[6]  P. Ward,et al.  Testicular distribution and toxicity of a novel LTA4H inhibitor in rats. , 2014, Toxicology and applied pharmacology.

[7]  R. Zubarev,et al.  Binding of Pro-Gly-Pro at the active site of leukotriene A4 hydrolase/aminopeptidase and development of an epoxide hydrolase selective inhibitor , 2014, Proceedings of the National Academy of Sciences.

[8]  G. Pier,et al.  BIIL 284 reduces neutrophil numbers but increases P. aeruginosa bacteremia and inflammation in mouse lungs. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[9]  L. Lands,et al.  A randomized double blind, placebo controlled phase 2 trial of BIIL 284 BS (an LTB4 receptor antagonist) for the treatment of lung disease in children and adults with cystic fibrosis. , 2014, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[10]  G. Salvesen,et al.  A remarkable activity of human leukotriene A4 hydrolase (LTA4H) toward unnatural amino acids , 2014, Amino Acids.

[11]  P. Jänne,et al.  Randomized, Double-Blind, Phase II Trial Comparing Gemcitabine-Cisplatin plus the LTB4 Antagonist LY293111 versus Gemcitabine-Cisplatin plus Placebo in First-Line Non–Small-Cell Lung Cancer , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[12]  L. Farkas,et al.  Blocking Macrophage Leukotriene B4 Prevents Endothelial Injury and Reverses Pulmonary Hypertension , 2013, Science Translational Medicine.

[13]  M. Kubo,et al.  Leukotriene B4 receptor BLT2 negatively regulates allergic airway eosinophilia , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[14]  Bastian R. Angermann,et al.  Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo , 2013, Nature.

[15]  H. Kantarjian,et al.  Two dosing regimens of tosedostat in elderly patients with relapsed or refractory acute myeloid leukaemia (OPAL): a randomised open-label phase 2 study. , 2013, The Lancet. Oncology.

[16]  Erden Banoglu,et al.  Overview of recent drug discovery approaches for new generation leukotriene A4 hydrolase inhibitors , 2013, Expert opinion on drug discovery.

[17]  John J. M. Wiener,et al.  Azabenzthiazole inhibitors of leukotriene A₄ hydrolase. , 2012, Bioorganic & medicinal chemistry letters.

[18]  A. Luster,et al.  Lipid‐cytokine‐chemokine cascades orchestrate leukocyte recruitment in inflammation , 2012, Journal of leukocyte biology.

[19]  Chang Hoon Lee,et al.  Resolvins as new fascinating drug candidates for inflammatory diseases , 2012, Archives of Pharmacal Research.

[20]  T. Yokomizo.  Leukotriene B4 receptors: novel roles in immunological regulations. , 2011, Advances in enzyme regulation.

[21]  M. Paige,et al.  Effect of the leukotriene A4 hydrolase aminopeptidase augmentor 4-methoxydiphenylmethane in a pre-clinical model of pulmonary emphysema. , 2011, Bioorganic & medicinal chemistry letters.

[22]  V. Jala,et al.  Deficiency of the Leukotriene B4 Receptor, BLT-1, Protects against Systemic Insulin Resistance in Diet-Induced Obesity , 2011, The Journal of Immunology.

[23]  H. Toh,et al.  Protective role of the leukotriene B4 receptor BLT2 in murine inflammatory colitis , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[24]  A. Gaggar,et al.  A Critical Role for LTA4H in Limiting Chronic Pulmonary Neutrophilic Inflammation , 2010, Science.

[25]  G. Morgan,et al.  Phase I/II clinical study of Tosedostat, an inhibitor of aminopeptidases, in patients with acute myeloid leukemia and myelodysplasia. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  J. Verweij,et al.  A Phase Ib dose-escalation study to evaluate safety and tolerability of the addition of the aminopeptidase inhibitor tosedostat (CHR-2797) to paclitaxel in patients with advanced solid tumours , 2010, British Journal of Cancer.

[27]  L. Karlsson,et al.  Leukotriene A(4) hydrolase inhibition attenuates allergic airway inflammation and hyperresponsiveness. , 2010, American journal of respiratory and critical care medicine.

[28]  M. Krohn,et al.  Discovery of 4-[(2S)-2-{[4-(4-chlorophenoxy)phenoxy]methyl}-1-pyrrolidinyl]butanoic acid (DG-051) as a novel leukotriene A4 hydrolase inhibitor of leukotriene B4 biosynthesis. , 2010, Journal of medicinal chemistry.

[29]  M. FourieAnne.  Modulation of inflammatory disease by inhibitors of leukotriene A4 hydrolase. , 2009 .

[30]  A. Harris,et al.  A First-in-Man Phase I and Pharmacokinetic Study on CHR-2797 (Tosedostat), an Inhibitor of M1 Aminopeptidases, in Patients with Advanced Solid Tumors , 2009, Clinical Cancer Research.

[31]  Brian Pease,et al.  Discovery of Leukotriene A4 Hydrolase Inhibitors Using Metabolomics Biased Fragment Crystallography† , 2009, Journal of medicinal chemistry.

[32]  H. Oettle,et al.  Randomized Double-Blind Phase II Trial Comparing Gemcitabine Plus LY293111 Versus Gemcitabine Plus Placebo in Advanced Adenocarcinoma of the Pancreas , 2009, Cancer journal.

[33]  H. Friess,et al.  The Role of PPARγ Receptors and Leukotriene B4 Receptors in Mediating the Effects of LY293111 in Pancreatic Cancer , 2009, PPAR research.

[34]  Gary Box,et al.  CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. , 2008, Cancer research.

[35]  B. Rigas,et al.  NO-Donating NSAIDs, PPARδ, and Cancer: Does PPARδ Contribute to Colon Carcinogenesis? , 2008, PPAR research.

[36]  Takao Shimizu,et al.  12(S)-hydroxyheptadeca-5Z, 8E, 10E–trienoic acid is a natural ligand for leukotriene B4 receptor 2 , 2008, The Journal of experimental medicine.

[37]  H. Magnussen,et al.  Effect of the oral leukotriene B4 receptor antagonist LTB019 on inflammatory sputum markers in patients with chronic obstructive pulmonary disease. , 2008, Pulmonary pharmacology & therapeutics.

[38]  A. Hoffman,et al.  Leukotriene B4 receptor antagonists as therapeutics for inflammatory disease: preclinical and clinical developments , 2007, Expert opinion on investigational drugs.

[39]  R. Gerszten,et al.  Inhibited Aortic Aneurysm Formation in BLT1-Deficient Mice1 , 2007, The Journal of Immunology.

[40]  James P Edwards,et al.  Anti-Inflammatory Activity of a Potent, Selective Leukotriene A4 Hydrolase Inhibitor in Comparison with the 5-Lipoxygenase Inhibitor Zileuton , 2007, Journal of Pharmacology and Experimental Therapeutics.

[41]  Jacques P. Brown,et al.  Clinical trial of a leucotriene B4 receptor antagonist, BIIL 284, in patients with rheumatoid arthritis , 2006, Annals of the rheumatic diseases.

[42]  G. Schwartz,et al.  Phase I and pharmacokinetic study of LY293111, an orally bioavailable LTB4 receptor antagonist, in patients with advanced solid tumors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Jesse D. Roberts,et al.  Inhibition of Atherogenesis in BLT1-Deficient Mice Reveals a Role for LTB4 and BLT1 in Smooth Muscle Cell Recruitment , 2005, Circulation.

[44]  T. Adrian,et al.  Effect of LY293111 in combination with gemcitabine in colonic cancer. , 2004, Cancer letters.

[45]  H. Kato,et al.  Randomized double-blind placebo-controlled trial of bestatin in patients with resected stage I squamous-cell lung carcinoma. , 2003, Journal of the National Cancer Institute.

[46]  T. Adrian,et al.  Leukotriene B4 receptor antagonist LY293111 inhibits proliferation and induces apoptosis in human pancreatic cancer cells. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[47]  J. Haeggström,et al.  Leukotriene A4 hydrolase. , 2002, Prostaglandins & other lipid mediators.

[48]  H. Showell,et al.  Leukotriene B4 Receptor Antagonism Reduces Monocytic Foam Cells in Mice , 2002, Arteriosclerosis, thrombosis, and vascular biology.

[49]  R. Murphy,et al.  Effect of peroxisome proliferator-activated receptor alpha activation on leukotriene B4 metabolism in isolated rat hepatocytes. , 2001, The Journal of pharmacology and experimental therapeutics.

[50]  G. Speck,et al.  In vitro and in vivo pharmacological characterization of BIIL 284, a novel and potent leukotriene B(4) receptor antagonist. , 2001, The Journal of pharmacology and experimental therapeutics.

[51]  W. Wahli,et al.  The PPARα–leukotriene B4 pathway to inflammation control , 1996, Nature.

[52]  C. Serhan,et al.  Lipoxin A4 and B4 inhibit leukotriene-stimulated interactions of human neutrophils and endothelial cells. , 1996, Journal of immunology.

[53]  J. Gierse,et al.  The bifunctional enzyme leukotriene-A4 hydrolase is an arginine aminopeptidase of high efficiency and specificity. , 1994, The Journal of biological chemistry.

[54]  F. Fitzpatrick,et al.  Leukotriene A4 hydrolase. Inhibition by bestatin and intrinsic aminopeptidase activity establish its functional resemblance to metallohydrolase enzymes. , 1991, The Journal of biological chemistry.

[55]  Vilmundur Gudnason,et al.  A variant of the gene encoding leukotriene A4 hydrolase confers ethnicity-specific risk of myocardial infarction , 2006, Nature Genetics.

[56]  M. Konopleva,et al.  Leukotriene B4 receptor inhibitor LY293111 induces cell cycle arrest and apoptosis in human anaplastic large-cell lymphoma cells via JNK phosphorylation , 2005, Leukemia.